FDA
-
-
-
-
-
-
-
Alkermes receives orphan drug status for alixorexton in U.S. and Europe
-
-
-
-
-
-
-
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
-
-
-
-
-
-
-
Alkermes (ALKS) PT Lowered to $43 at Piper Sandler
-
-
-
-
-
-
-
Alkermes increases Avadel acquisition offer to $22.50 per share
-
-
-
-
-
-
-
Alkermes plc Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
-
-
-
-
-
-
-
Alkermes plc Reports First Quarter 2024 Financial Results
-
329,752 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

